Sabus Steve M 4
4 · Turning Point Therapeutics, Inc. · Filed Jun 1, 2022
Insider Transaction Report
Form 4
Sabus Steve M
SVP & Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2022-05-31+165,000→ 165,000 totalExercise: $35.37Exp: 2032-05-30→ Common Stock (165,000 underlying) - Award
Common Stock
2022-05-31+36,667→ 36,667 total
Footnotes (2)
- [F1]Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
- [F2]25% of the shares vest on May 31, 2023 and 1/48th of the shares vest monthly thereafter over the next three years.